STAT-3 Inhibitory Bisabolanes from Carthamus glaucus

Basit Öğe Kaydı
dc.contributor.authorTaglialatela-Scafati, Orazio
dc.contributor.authorPollastro, Federica
dc.contributor.authorCicione, Lavinia
dc.contributor.authorChianese, Giuseppina
dc.contributor.authorBellido, Maria Luz
dc.contributor.authorMunoz, Eduardo
dc.contributor.authorOzen, Hasan Cetin
dc.date.accessioned2024-04-24T16:19:07Z
dc.date.available2024-04-24T16:19:07Z
dc.date.issued2012
dc.departmentDicle Üniversitesien_US
dc.description.abstractApart from a large amount (ca. 2.0%) of alpha-bisabolol beta-D-fucopyranoside (2a), the aerial parts of the Mediterranean weed Carthamus glaucus afforded an unusual triglyceride (E-2-crotonyl-1,3-distearolylglycerol, 7), two lipophilic flavonoids (6a,b), and a series of bisabolane fucopyranosides variously acylated on the sugar moiety (2b-e) or oxidized on the terpenoid core (3, 4a,b, 5a,b). The fucopyranoside 2a is more soluble in polar media and more versatile in terms of formulation than its aglycone [(-)-alpha-bisabolol, 1], an anti-inflammatory cosmetic ingredient in current short supply in its natural form. A comparative investigation of the activity of alpha-bisabolol (1a), the fucopyranoside 2a, and its senecioate 2b on transcription factors involved in inflammation and cancer pathways (NF-kappa B and STAT-3) showed only marginal activity on NF-kappa B inhibition for all compounds, while STAT-3 was inhibited potently by the fucoside 2a and, to a lesser extent, also by a-bisabolol. These observations qualify 2a as an easily available compound, both as an apoptotic lead structure and as a potential alternative to natural a-bisabolol (1) for pharmaceutical and/or cosmetic development.en_US
dc.description.sponsorshipRegione Piemonte; [SAF2010-19292]; [P09-CTS-4973]en_US
dc.description.sponsorshipWe are grateful to Regione Piemonte for supporting work at the Novara Laboratories. Mass and NMR spectra were recorded at Centro di Servizio Interdipartimentale di Analisi Strumentale, Universita di Napoli Federico II. E.M. acknowledges the support of grants SAF2010-19292 and P09-CTS-4973.en_US
dc.identifier.doi10.1021/np2008973
dc.identifier.endpage458en_US
dc.identifier.issn0163-3864
dc.identifier.issn1520-6025
dc.identifier.issue3en_US
dc.identifier.pmid22309250
dc.identifier.scopus2-s2.0-84859017459
dc.identifier.scopusqualityQ1
dc.identifier.startpage453en_US
dc.identifier.urihttps://doi.org/10.1021/np2008973
dc.identifier.urihttps://hdl.handle.net/11468/16406
dc.identifier.volume75en_US
dc.identifier.wosWOS:000301810700018
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherAmer Chemical Socen_US
dc.relation.ispartofJournal of Natural Products
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject[No Keyword]en_US
dc.titleSTAT-3 Inhibitory Bisabolanes from Carthamus glaucusen_US
dc.titleSTAT-3 Inhibitory Bisabolanes from Carthamus glaucus
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu